Seattle, WA Clinical Trials Report — May 2026

For Seattle residents exploring opportunities to contribute to medical science, May 2026 brings both urgent deadlines and exciting new research avenues. Across Seattle, a total of 1,247 clinical trials are actively recruiting participants across 349 research facilities, offering diverse opportunities for engagement.

Act Now: Trials Nearing Their Close

A significant number of clinical trials in Seattle are slated to conclude enrollment within the next 90 days. This urgency is particularly relevant for those considering participation, as 79 trials are closing soon. Among these, 9 trials are still actively seeking healthy volunteers, providing a chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also have limited time to join research. Conditions with trials closing soon include:

• Breast cancer (3 trials)
• HIV infections (2 trials)
• Advanced solid tumors (2 trials)
• Prostate cancer (2 trials)
• Amputation (2 trials)
• Multiple myeloma (2 trials)
• Heart failure (2 trials)
• PTSD (2 trials)
• Advanced solid tumor (1 trial)
• Alzheimer's disease (1 trial)

New Research Opportunities Emerge in Seattle

This month, Seattle saw the opening of 14 new clinical trials, maintaining a consistent pace compared to the 14 trials that launched in March and April 2026. These new studies bring fresh opportunities for participants to engage with cutting-edge treatments and diagnostic approaches.

May's new trials include several notable studies from major sponsors, addressing significant health challenges:

• Novo Nordisk A/S is sponsoring a major Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of a new compound in individuals with heart failure and excess body weight.
• Another significant Phase 3 trial from Novo Nordisk A/S is NCT07571109, "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea." This study involves 300 participants and focuses on weight loss and sleep apnea improvement.
• Definium Therapeutics US, Inc. is launching NCT07592689, "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)," a placebo-controlled study involving 165 participants to evaluate a new treatment for major depressive disorder.
• Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, is sponsoring NCT07603557, "Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)." This Phase 2 study with 52 participants aims to evaluate the safety and efficacy of Zola-cel in individuals with chronic immune thrombocytopenia and autoimmune hemolytic anemia.
• Stanford University is initiating NCT07601295, "Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)." This Phase 2 study with 90 participants compares a new treatment with standard care for pulmonary arterial hypertension.
• The Canopy Cancer Collective, LLC is leading NCT07605702, "The Canopy Cancer Collective Clinical Registry Protocol," a large observational registry protocol aiming for 100,000 participants to systematically collect comprehensive data on gastrointestinal cancer patients.

New trials this month are exploring a range of conditions, with the most frequent being:

• Obesity (2 trials)
• Autoimmune hemolytic anemia (1 trial)
• Chronic immune thrombocytopenia (1 trial)
• Colorectal cancer (1 trial)
• Gastrointestinal neoplasms (1 trial)
• GI cancer (1 trial)
• GI cancers (1 trial)
• Glymphatic system (1 trial)
• Heart failure (1 trial)
• HIV (1 trial)

Drug trials account for the largest share of new studies, with 7 new drug trials, followed by 5 other types of studies, and 2 biological studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are valuable opportunities to contribute to research. Of the 14 new trials launched this month, 3 are actively seeking healthy volunteers. Across Seattle, a total of 117 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Seattle's Leading Research Facilities

Seattle is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Washington (182 trials)
• Seattle Children's Hospital (170 trials)
• Fred Hutchinson Cancer Center (133 trials)
• Fred Hutch/University of Washington Cancer Consortium (80 trials)
• Swedish Medical Center-First Hill (72 trials)
• University of Washington Medical Center (53 trials)
• Swedish Cancer Institute (48 trials)
• Swedish Medical Center (43 trials)
• University of Washington Medical Center - Montlake (43 trials)
• Swedish Medical Center-Cherry Hill (42 trials)
• Swedish Medical Center-Ballard Campus (42 trials)
• Virginia Mason Medical Center (37 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the University of Washington and its medical centers, to specialized care at Seattle Children's Hospital and cancer research at Fred Hutchinson Cancer Center and the Swedish Cancer Institute.

Expanding Your Search: Nearby Washington Cities

While Seattle offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Washington State. Cities with active trials include:

• Tacoma (4 trials)
• Renton (3 trials)
• Bellevue (2 trials)
• Puyallup (1 trial)
• Redmond (1 trial)
• Vancouver (1 trial)
• Wenatchee (1 trial)
• Joint Base Lewis McChord (1 trial)

Who Can Participate? Eligibility and Key Sponsors

Participation in clinical trials is open to a diverse range of individuals. Of the 14 new trials launched this month, 1 includes children, and 10 include older adults, ensuring that various age groups have opportunities to contribute to medical science. Notably, no new trials this month are exclusively for females or males.

Academic institutions continue to play a vital role in Seattle's research ecosystem, with the University of Washington (5 trials) and Fred Hutchinson Cancer Center (2 trials) sponsoring the most new studies. Industry sponsors like Novo Nordisk A/S (2 trials), Definium Therapeutics US, Inc. (1 trial), and Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1 trial) are also driving significant research efforts.

As Seattle's robust research community continues to drive medical innovation, diverse opportunities will remain available for individuals to contribute to the future of healthcare and explore new treatment options.